Overexpression of transforming growth factor-beta1 in scirrhous carcinoma of the stomach correlates with decreased survival.
A retrospective study of 50 patients with scirrhous carcinoma of the stomach who had undergone surgery was performed to elucidate whether immunohistochemical overexpression of transforming growth factor-beta1 (TGF-beta1) could predict the patients' survival. To evaluate the proliferative activity of the tumor, the proliferating cell nuclear antigen (PCNA) index was used. Expression of TGF-beta1 was low in 27 patients and high in 23. Clinicopathological characteristics were not significantly different between the two groups with high and low TGF-beta1 expression. Tumors with higher TGF-beta1 expression had higher PCNA indices (p = 0.0467, unpaired Student's t test). The 5-year survival rate was 40.4% for the low TGF-beta1 group and 28.7% for the high TGF-beta1 group (p = 0.0388, log rank test). By multivariate analysis, pT, residual tumor, and TGF-beta1 were the independent prognostic factors. These results suggest that immunohistochemical expression of TGF-beta1 is one of the useful predictors for estimating the patients' survival in scirrhous carcinoma of the stomach particularly of the T3 and T4 stages.
Second Department of Surgery, Shimane Medical University, Izumo, Japan.
S
S
Kinugasa
S
S
Abe
M
M
Tachibana
Y
Y
Hishikawa
H
H
Yoshimura
N
N
Monden
D K
DK
Dhar
N
N
Nagasue
S
S
Nagaoka
D002293:Adenocarcinoma, Scirrhous / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D016212:Transforming Growth Factor beta / Q000096:biosynthesis*
D018809:Proliferating Cell Nuclear Antigen; D016212:Transforming Growth Factor beta